ECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logoECOG-ACRIN logo
  • Home
  • Archives
  • Contact
✕
July 19, 2023
July 19, 2023
Categories
  • Editorials

7 ways advocates have enhanced ECOG-ACRIN’s cancer research program

ECOG-ACRIN’s cancer research advocates recently reflected on their committee’s key accomplishments
Do you like it?
0 Read more
July 19, 2023
July 19, 2023
Categories
  • New Trials

Now Enrolling: The DIRECT study is testing how well FDG-PET/CT imaging can predict if treatment is working prior to surgery for patients with HER2-positive breast cancer

This study is for patients who have untreated, early-stage HER2-positive breast cancer
Do you like it?
0 Read more
July 19, 2023
July 19, 2023
Categories
  • New Trials

Now Enrolling: ComboMATCH treatment trial E4 is testing a new option for patients with advanced solid tumors that progress despite taxane chemotherapy

This study is for patients with solid tumors that are progressing after treatment with taxane therapies
Do you like it?
0 Read more
July 19, 2023
July 19, 2023
Categories
  • Ongoing Trials

A closer look at ECOG-ACRIN’s men’s cancer trials

These trials are exploring new treatment approaches for adults with prostate or penile cancer
Do you like it?
0 Read more
Prev page
12345
Next page

News, editorials, and perspectives for the cancer research advocacy community

✕

Categories

  • Editorials
  • New Trials
  • Ongoing Trials
  • Trial Results

Tags

Acute lymphoblastic leukemia Adolescents and young adults Advocacy Bladder cancer Breast cancer Caregiving Communication De-escalation Head and neck cancer Health equity HER2+ breast cancer Immune system therapy Immunotherapy In memory Kidney cancer Leukemia Lung cancer Lymphoma Mammography Mantle cell lymphoma Melanoma Multiple myeloma Myeloma NCI-MATCH Nose and sinus cancer Pancreatic cancer Pancreatic cysts Patient care Personalized medicine Personalized screening Personalized treatment Precision medicine Prevention Prostate cancer Renal cell carcinoma Research results Sarcoma Screening Side effects Squamous cell carcinoma Surveillance Survivorship Symptom management Targeted therapy Throat cancer

Resources

  • Active ECOG-ACRIN Trials
  • Advocacy Organizations
  • Myths and Facts
STAY UP TO DATE

Subscribe to receive updates from the ECOG-ACRIN advocacy committee.

Select list(s) to subscribe to


Office of Communications
1818 Market Street, Suite 3000
Philadelphia, PA 19103
Phone: 215.789.3631
www.ecog-acrin.org

Contact us with any questions

© 2019-2025 ECOG-ACRIN Cancer Research Group. All Rights Reserved. Designed by Create & Associates, Inc